ROS1 and Sinus bradycardia: Although generally well tolerated, rare but serious cardiac adverse effects have been reported.<h4>Case summary</h4>We report a 51-year-old woman with ROS1-mutant metastatic non-small cell lung cancer who developed symptomatic sinus bradycardia during entrectinib therapy.